Target Audience
- Researchers and scientists with some familiarity with DNA sequencing and genomics who are interested in the development and commercialization of long-read sequencing technologies.
- Readers interested in how university-born deep-tech companies progress from scientific research to product development, market expansion, and fundraising.
- Anyone interested in understanding the genomics industry through PacBio's business strategies, product evolution, management decisions, and challenges.
Executive Summary
- Pacific Biosciences (PacBio) is a DNA sequencing technology company founded in 2000, originating from single-molecule DNA analysis research at Cornell University.
- Although PacBio successfully commercialized long-read sequencing through its SMRT technology, its early products faced challenges related to sequencing accuracy, cost, throughput, and market adoption. The development of HiFi sequencing around 2018–2019 marked a major technological turning point.
- In 2018, Illumina announced a proposed acquisition of PacBio for approximately $1.2 billion, but the transaction was terminated in 2020 due to antitrust concerns. PacBio subsequently pursued expansion through a $900 million financing from a SoftBank-affiliated investment entity and the acquisition of Omniome in 2021.
- Beginning in 2024, deteriorating financial performance and substantial operating costs prompted a restructuring of the business. PacBio has since shifted its focus back toward high-accuracy long-read sequencing.
- PacBio's approximately 25-year history illustrates the challenges of turning pioneering scientific technology into a sustainable business, highlighting the distinction between solving technical problems and achieving lasting commercial success.
1. Introduction: What Kind of Company Is Pacific Biosciences?
Pacific Biosciences of California, Inc. (hereafter referred to as PacBio) is a DNA sequencing technology company headquartered in Menlo Park, California, United States.
The company was incorporated on July 14, 2000, and went public on NASDAQ in October 2010 under the ticker symbol PACB. [1]
PacBio is best known for developing and commercializing SMRT (Single Molecule, Real-Time) Sequencing, a technology that observes DNA synthesis by DNA polymerase in real time at the single-molecule level.
Its history, however, is not simply a story of technological success.
As PacBio worked to transform a pioneering scientific concept into commercial products and build a sustainable business in a highly competitive market, it encountered numerous technical, financial, and organizational challenges.
The company's history can be divided into six major phases.
-
2000–2010: Invention and commercialization of the technology
Building on single-molecule DNA analysis research originating at Cornell University, the company raised venture capital and eventually went public. -
2011–2017: Early product challenges and a redefinition of target applications
Despite launching an innovative sequencing platform, PacBio faced challenges involving cost, sequencing accuracy, and market adoption. Rather than competing directly with short-read sequencing across all applications, it increasingly focused on applications where long-read sequencing offered distinctive advantages. -
2018–2020: A technological turning point and a failed acquisition
Advances in high-accuracy long-read sequencing, particularly HiFi, strengthened PacBio's technological position. Illumina proposed acquiring the company, but the transaction was ultimately terminated due to antitrust concerns, leaving PacBio to continue independently. -
2021–2023: Aggressive investment and business expansion
PacBio raised substantial capital, acquired Omniome, and expanded into short-read sequencing alongside its long-read business. It introduced new products such as Revio while targeting clinical research and large-scale genomics. -
2024–2025: Slowing growth and strategic refocusing
The company faced reduced customer capital spending, pricing competition, and substantial research and development expenses. It responded with workforce reductions, cost-cutting measures, financial restructuring, and the discontinuation of further development of its high-throughput short-read platform. -
2026: Renewed concentration on long-read sequencing
PacBio sold certain short-read sequencing assets to Illumina. With a new CEO, the company has focused on reducing the cost of high-accuracy long-read sequencing and expanding into large-scale genomics and AI-related applications.
An important distinction throughout this history is the difference between what PacBio has consistently maintained and what it has repeatedly changed.
What has remained consistent is its technological direction: using SMRT technology to reveal genomic information that conventional DNA sequencing methods could not easily capture.
Meanwhile, its target markets, product portfolio, management team, sales strategy, and financing approach have changed considerably.
The contrast between the diversification strategy launched in 2021 and the renewed strategic focus of 2025–2026 is particularly noteworthy.
The following sections examine PacBio's origins, technological development, product evolution, leadership changes, capital strategy, and responses to major challenges.
One historical distinction is worth emphasizing at the outset. The company's incorporation in 2000 should not be confused with the full-scale launch of its business activities around 2004. Its 2010 IPO prospectus explicitly identifies July 2000 as the incorporation date, while other accounts place the transition from university research to substantial fundraising and business operations around 2003–2004. [1]
2. Origins of the Technology and Founding of the Company (2000–2010)
2-1. The Original Idea: Reading Individual DNA Molecules Without Amplification
PacBio's origins can be traced to nanotechnology research at Cornell University in the United States.
At the time, DNA sequencing technologies faced significant technical limitations.
Many approaches required DNA to be fragmented into short pieces or amplified before measurement. These characteristics made it difficult to accurately analyze long repetitive regions and complex structural variations.
Stephen Turner and Jonas Korlach, who played central roles in the technology underlying PacBio, investigated ways to observe DNA polymerase synthesizing DNA in real time at the single-molecule level.
This work eventually became the foundation of SMRT Sequencing.
A critical component of SMRT technology is the Zero-Mode Waveguide (ZMW), a nanoscale optical observation structure.
ZMWs enable fluorescent signals associated with DNA synthesis to be observed within extremely small volumes.
This allows relatively long DNA sequences to be read directly without requiring large-scale amplification of the DNA molecules.
However, while the technology offered substantially longer reads, the accuracy of individual reads was initially limited.
Addressing this limitation eventually led to the development of HiFi sequencing.
2-2. Who Founded the Company?
Understanding PacBio's founding requires distinguishing between the researchers who originated the underlying scientific work and the individuals involved in establishing the company.
The main figures include the following.
| Person | Main Role |
|---|---|
| Stephen Turner | Led commercialization efforts; served as the company's first CEO and later as CTO |
| Jonas Korlach | Co-inventor of SMRT technology; joined in 2004 as the company's eighth employee and later became CSO |
| Harold Craighead | Contributed to the research foundations in nanofluidics and nanostructures |
| Watt Webb | Contributed to the academic foundations in optics and single-molecule observation |
A useful interpretation is that the technology originated in research at Cornell University and was subsequently commercialized by Turner and his colleagues.
Materials from the Science Coalition describing university spinouts identify Craighead and Webb as founders, while PacBio's IPO prospectus states that Turner co-founded the company in July 2000.
An article about Turner published by the Wisconsin Alumni Association also describes how he left his university position in 2003 to focus on entrepreneurship, secured financing later that year, relocated to Silicon Valley, and launched full-scale operations in 2004. [1]
The progression from research to commercialization can be summarized as follows.
Academic Research (1990s–Early 2000s)
Researchers explored the possibility of observing individual molecules by combining biophysics, optics, and nanofabrication.
July 2000: Incorporation as Nanofluidics, Inc.
The corporation that later became PacBio was established in Delaware.
2003–2004: Launch of Full-Scale Business Operations
Turner transitioned from academic research to entrepreneurship, pursued venture financing, and established business operations in Menlo Park.
2005: Renaming to Pacific Biosciences
The company adopted a name reflecting its direction as a life sciences technology business focused on DNA analysis.
2010: Initial Public Offering
PacBio went public on NASDAQ and raised substantial funding to support commercial production and business expansion.
2-3. Why Did the Company Require So Much Capital?
PacBio differed considerably from a typical bioinformatics software company.
To build a commercial product, it needed to develop and integrate several complex technologies simultaneously.
These included:
- ZMW chips manufactured through nanofabrication
- Biochemical technologies such as DNA polymerases and fluorescently labeled nucleotides
- Highly sensitive optical detection systems
- Algorithms capable of converting complex optical signals into DNA sequences
- Instrument manufacturing, quality control, and customer support infrastructure
Consequently, there was a substantial gap between demonstrating that the technology worked in a laboratory and building a reliable product that customers could routinely operate.
In its 2010 IPO, PacBio issued 12.5 million shares at $16 per share, raising $200 million in gross proceeds. The amount expected to be received by the company before underwriting commissions and related deductions was approximately $186 million. [1]
One particularly important point is that PacBio went public before launching its first commercial DNA sequencer.
At the time of its IPO, the prospectus characterized the company as being in the development stage, with substantially all revenue originating from research grants rather than established commercial product sales.
In other words, the company was able to raise substantial capital based on expectations surrounding its technology.
At the same time, it became subject to the growth expectations associated with being a publicly traded company before the commercial viability of its products and revenue model had been fully established.
3. Product Evolution and Changes in Strategic Focus
PacBio's product history is also a history of attempts to make SMRT technology commercially viable through improvements in sequencing accuracy, throughput, cost, and usability.
3-1. Major Sequencing Platforms
| Year | Product | Key Features and Strategic Position |
|---|---|---|
| 2011 | PacBio RS | First commercial sequencing platform; introduced SMRT technology to research laboratories and demonstrated the value of long-read sequencing |
| 2013 | PacBio RS II | Improved performance and throughput; expanded applications in microbial genomics, plant and animal genome sequencing, and structural variation analysis |
| 2015 | Sequel | Smaller instrument with higher throughput; new SMRT Cells improved instrument footprint and sequencing economics |
| 2019–2020 | Sequel II / Sequel IIe | Enabled broader adoption of HiFi sequencing; strengthened high-accuracy long-read sequencing and improved onboard analysis and computational efficiency |
| 2023 | Revio | High-throughput platform for large-scale genomics; aimed to reduce the cost per human genome |
| 2023 | Onso | High-accuracy short-read sequencing platform based on Omniome's SBB technology; subsequently affected by a shift in business strategy |
| Announced in 2024 | Vega | Smaller, lower-cost long-read sequencing system targeting laboratories that do not require the throughput of Revio |
Overall, the company's technological priorities evolved from enabling long reads to improving their accuracy, and then toward reducing cost and increasing throughput for large-scale sequencing. [2][3]
Between 2021 and 2023, PacBio also expanded into short-read sequencing, before returning its strategic focus to long-read technology during 2025–2026.
3-2. 2011–2014: Why Was the First PacBio RS Commercially Challenging?
PacBio launched its first commercial product, the PacBio RS, in 2011.
At that time, short-read DNA sequencing platforms, particularly those from Illumina, were rapidly gaining adoption.
Their major advantages included relatively inexpensive, high-accuracy analysis of large volumes of DNA sequence data.
The PacBio RS, by contrast, offered substantially longer individual reads.
However, its early single-molecule read accuracy was relatively low, and it also faced limitations involving instrument price, operating costs, and throughput.
As a result, replacing short-read sequencing with PacBio technology for routine DNA analysis was not economically justified in many applications.
A significant strategic adjustment was therefore to identify research applications where long reads offered unique value.
Examples included:
- Complete sequencing of complex microbial genomes
- De novo assembly of plant and animal genomes
- Analysis of long repetitive DNA regions
- Full-length RNA isoform sequencing
- Analysis of complex structural variants
This represented a shift away from trying to perform the same tasks as existing sequencing platforms at a lower cost, toward solving problems that existing platforms struggled to address.
The PacBio RS II, introduced in 2013, improved instrument performance for these research applications.
3-3. 2013–2017: The Roche Partnership and Its Termination
During this period, PacBio attempted to enter clinical markets through a partnership with Roche, a major diagnostics company.
In September 2013, the two companies signed an agreement to develop and commercialize clinical diagnostic products using SMRT technology.
Under the arrangement, PacBio was responsible for technology development, product development, and manufacturing, while Roche received exclusive commercialization rights in the human in vitro diagnostics market.
PacBio ultimately received a total of $75 million under the agreement.
However, Roche notified PacBio in December 2016 that it intended to terminate the agreement, which ended in February 2017.
Roche explained that it was concentrating its efforts on its own sequencing strategy. [2]
For PacBio, the termination meant losing a major potential distribution channel into clinical diagnostics.
On the other hand, it also allowed the company to pursue clinical research and analysis markets using its Sequel-based technology independently or through other partnerships.
This episode is important for understanding the company's subsequent strategy.
Partnerships with large corporations can provide capital and market access, but they also expose a smaller company to changes in the strategic priorities of its partners.
The PacBio–Roche relationship illustrates this risk.
3-4. 2018–2020: HiFi as a Major Technological Turning Point
One of the most important technological turning points in PacBio's history was the development of HiFi sequencing.
The central limitation of early SMRT sequencing was that individual long reads could contain relatively high error rates.
To address this problem, PacBio advanced Circular Consensus Sequencing (CCS).
In CCS, a circularized DNA molecule is read multiple times by the same polymerase, and the resulting observations are combined to generate a more accurate consensus sequence.
The basic principle underlying HiFi sequencing can be summarized as follows.
- A DNA molecule is circularized to create a template for SMRT sequencing.
- The same DNA molecule is read multiple times.
- Each individual pass may contain different sequencing errors.
- Information from multiple passes is combined to generate a consensus sequence.
- The resulting HiFi read combines a long read length with high sequence accuracy.
A study published in Nature Biotechnology in 2019 reported an accuracy of 99.8% for long reads averaging approximately 13.5 kb. [4]
This was a significant achievement.
Historically, sequencing technologies had often involved a trade-off between technologies that could generate long reads but had limitations in accuracy, and technologies that generated short reads with high accuracy.
HiFi substantially changed this distinction.
This did not mean that long-read sequencing became superior to short-read sequencing for every application.
However, the ability to combine long reads with high accuracy represented a major advance for applications such as structural variation analysis, repetitive regions, haplotype resolution, and complex disease-associated genomic regions.
The Sequel II, introduced in 2019, offered approximately eight times the data output of the original Sequel platform.
The Sequel IIe, introduced in 2020, added enhanced onboard computational processing, helping reduce the computational costs associated with analyzing sequencing data. [2][3]
The transition can be summarized as follows.
| Before HiFi | After HiFi |
|---|---|
| Long read length was the primary value proposition | Combined long read length and high accuracy became the key value proposition |
| Primarily specialized research applications | Broader applications, including human genome research |
| Data processing represented an additional adoption barrier | Integrated software and improved computational processing |
| Technological advantages could be difficult to communicate | Stronger value proposition for integrated analysis of structural and small variants |
This was more than a routine instrument upgrade.
It represented a fundamental change in the value that PacBio could deliver to customers.
4. Illumina's Proposed Acquisition and Its Termination (2018–2020)
In November 2018, Illumina, a leading company in short-read DNA sequencing, announced plans to acquire PacBio for approximately $1.2 billion.
Had the acquisition been completed, Illumina would have owned both short-read and long-read sequencing technologies.
For PacBio, the transaction offered potential access to Illumina's sales channels, customer base, manufacturing capabilities, and research and development resources.
However, competition authorities viewed the transaction differently.
In December 2019, the U.S. Federal Trade Commission (FTC) challenged the proposed acquisition.
The FTC argued that PacBio could become an important future competitor to Illumina and that the acquisition could reduce competition in the next-generation DNA sequencing market. [5]
This represented the competition authority's assessment, rather than a final legal determination that the transaction was unlawful.
On January 2, 2020, the companies announced the termination of the merger agreement.
Illumina agreed to pay PacBio a termination fee of $98 million. [5]
This episode had two important implications.
First, it demonstrated that long-read sequencing technology had become sufficiently valuable to attract a major acquisition proposal from an established industry leader.
Second, PacBio remained responsible for independently financing its operations, developing commercial capabilities, and expanding its sales network.
There is also an interesting contrast with later developments.
In 2020, Illumina's proposed acquisition of PacBio as an entire company was terminated.
In 2026, however, PacBio sold certain short-read sequencing assets to Illumina.
These transactions were fundamentally different in scope and economic significance: the earlier transaction concerned the entire company, while the later transaction involved selected technology assets.
5. 2021–2023: Major Financing and Aggressive Business Expansion
This period represented one of PacBio's most ambitious attempts to expand the scale of its business.
5-1. The $900 Million SoftBank Financing
In February 2021, PacBio announced a $900 million financing through convertible senior notes issued to an investment entity affiliated with SoftBank Group.
The notes were due in 2028, with an initial conversion price of $43.50 per share. [6]
It is important to recognize that this was not a straightforward equity investment.
The financing involved convertible debt.
Conversion could result in shareholder dilution, while notes that were not converted would require repayment or refinancing.
At the time, PacBio stated that the capital would be used to accelerate product development, commercialization, and expansion into large-scale genomic sequencing markets.
The transaction substantially increased the company's capacity to invest.
5-2. Expanding into Short-Read Sequencing Through the Omniome Acquisition
In September 2021, PacBio acquired Omniome, a company developing short-read sequencing technology.
Omniome had developed a technology called Sequencing by Binding (SBB), intended to enable high-accuracy short-read DNA sequencing.
The acquisition reflected PacBio's ambition to become a company with two technological pillars.
| Technology | Main Characteristics | Target Applications |
|---|---|---|
| HiFi / SMRT | High-accuracy long-read sequencing | Complex structural variation, genome assembly, full-length RNA analysis, and related applications |
| SBB / Omniome | High-accuracy short-read sequencing | High-accuracy small-variant analysis, cancer research, and a broad range of other applications |
In connection with the acquisition, PacBio also completed a $300 million PIPE (Private Investment in Public Equity) financing.
The company additionally acquired Circulomics, a developer of DNA sample preparation technology, in 2021.
By the end of that year, PacBio held approximately $1.04 billion in cash, cash equivalents, and investments, providing substantial financial resources for product development and business expansion. [6][7]
However, this expansion also increased the scale and complexity of the organization.
It raised the level of future revenue growth needed to support operations and increased the organizational burden of any subsequent restructuring.
5-3. Revio and the Expansion into Large-Scale Genomics
Revio was announced in October 2022 and began shipping in March 2023.
It became PacBio's flagship high-throughput long-read sequencing platform.
At launch, PacBio stated that a single Revio system was designed to sequence up to approximately 1,300 human genomes per year at 30-fold coverage, with sequencing costs of less than $1,000 per genome. [3]
The strategic objective was to make long-read sequencing applicable not only to specialized research institutions but also to genomic studies involving thousands or tens of thousands of human genomes.
PacBio reported receiving orders for 76 Revio systems in the fourth quarter of 2022.
These figures represented orders, not necessarily systems already installed at customer sites.
Revio therefore marked an important step in PacBio's efforts to extend long-read sequencing from specialized applications into large-scale human genomics research.
5-4. Launching Onso
In August 2023, PacBio began commercial shipments of Onso, its short-read sequencing system based on Omniome technology. [3]
At that point, the ability to offer high-accuracy sequencing in both long-read and short-read formats had become an important element of PacBio's corporate strategy.
However, this dual-platform strategy did not last long.
Deteriorating market conditions beginning in 2024 prompted another major strategic reassessment.
6. 2024–2026: Restructuring and Strategic Refocusing
6-1. 2024: A Gap Between Growth Expectations and Actual Revenue
PacBio generated approximately $200 million in revenue in 2023.
In 2024, however, annual revenue declined to approximately $154 million. [7]
During 2024, the company implemented cost-reduction measures, including workforce reductions and the closure of its San Diego site.
The San Diego operation had been part of the expanded development organization associated with the Omniome acquisition in 2021.
This illustrates how an organization expanded through acquisition later had to be reduced within only a few years.
At the same time, PacBio announced Vega, a smaller long-read sequencing platform, in November 2024.
Its announced U.S. list price was $169,000.
Vega was intended to make HiFi sequencing accessible to laboratories that did not require the throughput offered by Revio. [3]
Thus, PacBio complemented its strategy of targeting large sequencing centers with Revio by attempting to reach a broader range of laboratories through a smaller instrument.
6-2. 2025: Discontinuing Further Development of the Short-Read Platform
In 2025, PacBio reassessed its business priorities in response to financial pressures and market conditions.
Its principal actions included:
- Concentrating research and development resources on HiFi-based long-read sequencing
- Discontinuing development of its high-throughput short-read sequencing platform
- Restructuring its sales organization and reducing headcount
- Targeting approximately $45–50 million in annual non-GAAP operating expense reductions
- Seeking improvements in instrument efficiency and consumables costs to strengthen profitability
At the time, the company stated that it would continue sales and customer support for the existing Onso platform.
Therefore, it would be inaccurate to conclude that PacBio immediately terminated all short-read operations in 2025. [7]
Annual revenue in 2025 recovered modestly to approximately $160 million, but remained below its 2023 level.
The challenges were not limited to technology development.
Demand was also influenced by external factors such as research institution budgets, uncertainty surrounding NIH and other research funding, tariffs, and customer decisions regarding purchases of major laboratory equipment.
6-3. 2026: Selling Short-Read Technology Assets to Illumina
On February 2, 2026, PacBio announced that it had sold certain intellectual property and related assets associated with short-read sequencing to Illumina.
The transaction generated approximately $48.1 million in net cash proceeds. [7][8]
This marked a significant strategic reversal.
In 2021, owning both long-read and short-read technologies had been an important part of the company's growth strategy.
By 2026, concentrating resources on long-read sequencing had become the priority.
In approximately four and a half years, PacBio had moved from diversification to renewed specialization.
However, the transaction involved certain short-read assets.
It would not be accurate to assume that all technologies and assets obtained through the Omniome acquisition were sold.
6-4. Developments in 2026
On August 5, 2026, Mark Van Oene succeeded Christian Henry as CEO.
In the second-quarter results announced that day, PacBio reported quarterly revenue of $39 million.
Cash, cash equivalents, and investments at the end of the quarter totaled approximately $236.9 million. [8]
The company also began commercial deployment of SPRQ-Nx chemistry and announced a human whole-genome sequencing price of $345 per genome under specified conditions.
This figure should be distinguished from the total cost of a complete clinical workflow, which could include sample collection, preparation, downstream analysis, interpretation, and other expenses.
In October 2026, PacBio announced a multiyear collaboration with Verily Health to integrate long-read genomic data with clinical and health data and AI research infrastructure. [8]
These developments suggest that the company is expanding its focus beyond improving sequencing instruments alone.
The strategic direction increasingly involves producing large quantities of high-quality genomic data and enabling their use in AI research, drug discovery, and related applications.
As of the research cutoff date for this article, November 3, 2026, PacBio's third-quarter financial results had not yet been released.
The third-quarter earnings announcement was scheduled for November 4, 2026, U.S. time, making the second quarter the latest publicly reported quarterly financial period at the time of writing.
7. Changes in Leadership and Human Resources
PacBio's leadership history reflects a transition from research-driven management to commercial product development, and subsequently toward operational efficiency and financial discipline.
7-1. Major CEO Transitions
| Period | CEO | Main Characteristics |
|---|---|---|
| 2000–2004 | Stephen Turner | Founding and initial technology development |
| 2004–2011 | Hugh Martin | Organizational development, product development, and IPO |
| 2012–2020 | Michael Hunkapiller | Commercialization and improvement of sequencing platforms; development of HiFi |
| 2020–August 2026 | Christian Henry | Major financing, acquisitions, product expansion, and restructuring |
| August 2026–Present | Mark Van Oene | Long-read-centered operations, commercialization, and profitability improvements |
These management transitions correspond to changes in the company's major business challenges. [1][8]
7-2. Michael Hunkapiller: From Research and Development to Commercialization
Michael Hunkapiller served as CEO from 2012 to 2020.
He had previously held leadership positions at Applied Biosystems and brought substantial experience in the industrial commercialization of DNA sequencing instruments.
His appointment in 2012 symbolized PacBio's transition from a research and development-oriented company toward one increasingly focused on improving and selling commercial products.
During his tenure, the company introduced the RS II, Sequel, and Sequel II, while HiFi technology also advanced significantly.
7-3. Christian Henry: Expansion, Financing, and Restructuring
Christian Henry became CEO in 2020 and led the company until August 2026.
Major events during his tenure included the substantial financing from a SoftBank-affiliated investment entity, the acquisitions of Omniome and Circulomics, the introduction of Revio and Onso, and the subsequent restructuring of the company.
His leadership period therefore encompassed both aggressive investment for growth and a later return to strategic focus.
7-4. Mark Van Oene: Commercialization and Operating Efficiency
Mark Van Oene joined PacBio as COO in 2021 and became CEO in August 2026.
Before joining PacBio, he had worked at Illumina in global sales and business operations.
His background is relevant to the company's current priorities, including increasing instrument adoption, expanding consumables revenue, and improving cost efficiency.
7-5. Continuity of the Founding Technology
Another distinctive feature of PacBio is the long-standing scientific contribution of Jonas Korlach, one of the founding figures behind SMRT technology.
While the company has undergone several CEO transitions, it has continuously developed and improved its core SMRT technology.
In terms of leadership strategy, PacBio has combined scientific specialists with executives who gained experience at established sequencing companies such as Applied Biosystems and Illumina.
However, the extent to which these leadership appointments directly contributed to financial improvements cannot be quantitatively established from public information alone.
8. Capital Strategy and Financial Evolution
8-1. Major Capital Events
Understanding PacBio's history requires examining not only its technologies and products but also its financing decisions and capital structure.
| Year | Capital Event | Strategic Significance |
|---|---|---|
| 2000s | Venture capital financing | Supported research and development needed to commercialize the underlying technology |
| 2010 | IPO raising $200 million in gross proceeds | Funded commercialization, manufacturing, and sales infrastructure |
| 2013–2016 | Total payments of $75 million from Roche | Supported joint development of clinical diagnostic products |
| 2020 | $98 million termination fee from Illumina | Provided capital following the termination of the proposed acquisition |
| 2021 | $900 million in convertible debt financing from a SoftBank-affiliated entity | Enabled large-scale growth investment |
| 2021 | $300 million PIPE financing | Supported the Omniome acquisition and business expansion |
| 2023 | Exchange of $441 million in convertible notes | Extended the maturity of part of the debt from 2028 to 2030 |
| 2024 | Debt restructuring | Adjusted financial obligations and capital structure |
| 2026 | Sale of short-read assets, generating $48.1 million in net cash proceeds | Provided capital and supported renewed focus on long-read sequencing |
The amounts in this table represent announced transaction values or financing amounts and should not be added together as though they were comparable cash flows within a single period. [1][2][5][6][7]
One of the most important elements of PacBio's capital strategy was the 2021 convertible debt financing.
The $900 million transaction provided considerable flexibility for growth investment.
However, it also created obligations associated with the notes' future maturity.
In 2023, approximately $441 million of convertible notes were exchanged for notes maturing in 2030.
The company also implemented further debt restructuring in 2024.
These developments illustrate that successfully raising capital and establishing a sustainable, profitable business are separate challenges.
8-2. Recent Revenue Trends
PacBio's revenue between 2022 and 2025 illustrates both its expansion and subsequent slowdown.
| Year | Revenue (USD Millions) | Year-over-Year Trend |
|---|---|---|
| 2022 | 128.304 | — |
| 2023 | 200.521 | Significant increase |
| 2024 | 154.014 | Decline |
| 2025 | 160.005 | Modest recovery |
Source: SEC Form 10-K filings for the respective years. [7]
Revenue reached approximately $200 million in 2023 but fell to approximately $154 million in 2024.
Although 2025 revenue showed a modest recovery, it remained below the 2023 level.
Key financial figures include the following.
| Metric | Value | Additional Information |
|---|---|---|
| 2025 revenue | $160.0 million | Approximately 3.9% year-over-year growth |
| 2025 GAAP net loss | $546.4 million | Includes substantial noncash expenses |
| 2025 consumables revenue | $81.9 million | Approximately 16.4% year-over-year growth |
| Cash and investment balance at June 2026 | $236.9 million | Total cash, cash equivalents, and investments |
Sources: 2025 Form 10-K, full-year 2025 financial results, and second-quarter 2026 financial results. [7][8]
An important qualification concerns the $546.4 million GAAP net loss reported for 2025.
This does not mean the company lost an equivalent amount of cash through its business operations.
The reported loss included substantial noncash accounting expenses, including charges related to acquired intangible assets.
Nevertheless, the figure should not obscure the fact that major historical investments had not yet generated the expected level of sustainable earnings, and the company's financial obligations remained substantial.
8-3. The Relationship Between Instrument Sales and Consumables Revenue
An important characteristic of PacBio's business model is that revenue does not come exclusively from instrument sales.
The basic business structure can be described in three steps.
-
Install sequencing instruments in laboratories and genomic analysis facilities.
Customers purchase or install platforms such as Revio and Vega. -
Generate recurring sequencing activity.
As laboratories conduct sequencing runs, they purchase consumables such as SMRT Cells, reagents, and library preparation kits. -
Generate ongoing consumables revenue.
Revenue depends not only on the number of installed instruments but also on how frequently those instruments are used.
PacBio's 2025 revenue composition was approximately as follows.
| Revenue Category | 2025 Revenue |
|---|---|
| Instruments | $53.8 million |
| Consumables | $81.9 million |
| Services and other revenue | $24.2 million |
Instrument revenue declined from the previous year, while consumables revenue increased. [7]
This suggests that evaluating PacBio's future performance requires looking beyond instrument sales alone.
The utilization of installed systems and the amount of recurring consumables revenue they generate are also important indicators.
9. Challenges PacBio Has Faced and How It Responded
PacBio's history reflects the interaction of technical, commercial, financial, and organizational challenges.
9-1. Overview of Major Challenges and Responses
| Challenge | Response | Assessment as of 2026 |
|---|---|---|
| Limited accuracy of early individual reads | Development of CCS and HiFi | Substantial technological improvement |
| Low throughput and high sequencing costs | Progression from RS II to Sequel, Sequel II, and Revio | Continued improvements in performance and cost |
| Limited target market | Expansion from specialized applications into large-scale human genomics | Larger market opportunity, but sustainable profitability remains unproven |
| Entry into clinical markets | Partnership with Roche | Direct route through the partnership ended following termination |
| Failure of the proposed Illumina acquisition | Continued independent operations and major financing | Independence maintained, but financial challenges remained |
| Expansion into short-read sequencing | Omniome acquisition and Onso launch | Followed by a strategic return to long-read sequencing |
| High research, development, and operating expenses | Workforce reductions, site closures, and debt restructuring | Cost reductions pursued, but sustainable profitability not yet established |
| High investment barrier for large instruments | Vega introduction and reductions in sequencing cost | Impact on market adoption remains to be evaluated |
9-2. Technical Success and Business Success Are Different
Overall, PacBio has addressed many of its technical challenges through sustained innovation, while its business and financial challenges remain only partially resolved.
The development of HiFi and improvements in sequencing platforms are supported by scientific publications and documented product specifications.
However, the available financial data do not yet establish when, or to what extent, those technological achievements will translate into sustainable profits.
This distinction is essential to understanding PacBio's corporate history.
Possessing a valuable technology does not automatically mean that a company can consistently generate profits from it.
10. Current Areas of Focus and Future Priorities
As of 2026, PacBio is seeking to expand the value of high-accuracy long-read sequencing across several important markets.
10-1. Rare Diseases and Human Genomics Research
Long-read sequencing can help analyze structural variations, repetitive regions, and complex genomic loci that are difficult to characterize using short-read sequencing alone.
Rare disease research and potential future clinical applications represent important target markets.
10-2. Cancer and Epigenomics Research
PacBio's technology can provide information about DNA sequences alongside features such as DNA methylation.
These capabilities may support cancer research and investigations into the molecular mechanisms underlying disease.
10-3. Full-Length RNA Sequencing and Drug Discovery
Technologies such as Kinnex can be used to analyze full-length transcripts and alternative splicing structures.
In 2026, PacBio also announced a collaboration with TychoBio, a company focused on AI-driven drug discovery. [8]
10-4. Large-Scale Genomic Data and AI
Through collaborations with organizations such as Verily Health, PacBio aims to connect high-quality genomic data with clinical and health-related datasets.
Such integration may support AI model development and large-scale biomedical research. [8]
However, these areas represent strategic priorities announced by PacBio.
They should not all be interpreted as mature businesses already generating substantial revenue.
In particular, the financial contribution of AI-related collaborations remains to be demonstrated.
11. Five Lessons from PacBio's Corporate History
The following observations are interpretations based on the publicly available information discussed above.
11-1. There Can Be a Long Delay Between a Technological Breakthrough and Commercial Success
PacBio began developing SMRT technology in the early 2000s and launched its first commercial product in 2011.
However, the combination of long reads and high accuracy was not substantially achieved until around 2018–2019.
Additional investment in platforms such as Revio, new sequencing chemistry, and computational technologies was then required to bring the cost of sequencing closer to levels suitable for large-scale genomic research.
The process from demonstrating the scientific potential of a technology to enabling widespread, economically viable adoption can take many years.
This is an important characteristic of commercializing university-born deep technology.
11-2. PacBio Has Evolved from Selling a New Technology to Creating New Analytical Opportunities
In the early years, the ability to generate long DNA reads was itself the principal distinguishing feature.
Over time, PacBio increasingly identified research problems for which long-read sequencing offered clear advantages.
Examples include structural variation analysis, full-length RNA sequencing, and rare disease research.
This change is significant.
For customers, the ultimate value is not the long sequencing read itself, but the scientific results, diagnostic insights, or drug discovery opportunities that the data may enable.
A defining feature of PacBio's market strategy has therefore been not merely improving technical specifications, but developing applications where those improvements translate into meaningful research value.
11-3. Major Financing Expands Opportunities, but Can Also Increase Organizational Complexity
The substantial financing and Omniome acquisition in 2021 gave PacBio considerable room to pursue growth.
However, the restructuring of 2024–2026 suggests that expanding into additional business areas was not necessarily the optimal long-term strategy.
In particular, investments in short-read sequencing were followed by a strategic reversal that involved significant restructuring costs.
Abundant capital can create opportunities for technological development and acquisitions.
At the same time, developing multiple technology platforms in parallel can increase organizational complexity and make resource allocation more difficult.
11-4. PacBio's Business Is Highly Sensitive to Its External Environment
Many of PacBio's customers are universities, research institutions, and genomic research centers.
Demand is therefore influenced by factors such as research grants, capital expenditure budgets, government policies, and international trade conditions.
This is one reason why having a technologically strong product does not necessarily translate into stable revenue growth.
For expensive research instruments in particular, customers may recognize the scientific value of a technology while postponing adoption because of budget constraints or capital spending priorities.
11-5. Technological Competitiveness and Corporate Profitability Must Be Evaluated Separately
As of 2026, PacBio's long-read sequencing technology has scientific validation and clearly identified applications.
However, turning technological competitiveness into sustained profitability requires an appropriate balance among instrument sales, consumables utilization, manufacturing costs, research and development spending, and operating expenses.
Future evaluations of PacBio should therefore monitor indicators such as:
- Growth in consumables revenue
- Utilization of installed sequencing systems
- Operating cash flow
- Management of debt obligations
- Customer acquisition in large-scale genomic sequencing
- Recurring revenue generated by platforms such as Revio and Vega
Technical performance metrics and financial sustainability metrics should be evaluated separately.
12. Conclusion: What Has PacBio Achieved, and What Challenges Remain?
PacBio's history can be characterized as the story of a company that spent more than two decades commercializing a university-born technology while repeatedly rebuilding its market strategy and management structure.
One of its greatest strengths has been its consistent investment in a core technology and its ability to develop that technology into a competitive family of HiFi sequencing products.
SMRT technology originally demonstrated the possibility of reading long DNA molecules directly.
CCS and HiFi subsequently addressed one of the major limitations of early long-read sequencing: read accuracy.
Platforms such as Sequel II, Revio, and Vega further expanded sequencing capacity, improved cost efficiency, and broadened the range of laboratories that could potentially adopt the technology.
At the same time, the long development cycle, substantial capital requirements, dependence on external market conditions, and challenges associated with diversification repeatedly placed pressure on the company's finances and organization.
The Roche partnership in 2013, Illumina's proposed acquisition in 2018, the SoftBank-affiliated financing and Omniome acquisition in 2021, and the renewed strategic focus during 2025–2026 can each be understood as responses to different business challenges.
What is particularly interesting is that PacBio continued advancing SMRT-based high-accuracy long-read sequencing despite these major changes in its business strategy.
As of 2026, technological progress continues, while the company remains in a period in which the success of its strategic refocusing and profitability improvements has yet to be fully demonstrated.
Whether PacBio can make long-read genomic sequencing accessible to a substantially broader market and convert that adoption into sustainable revenue and profits will be a central factor shaping the next chapter of its history.
PacBio's experience is also instructive for researchers in genomics and other scientific fields.
When a new measurement technology emerges, its scientific value may not immediately be recognized as commercial value.
Beyond improving technical performance, the company must identify research questions that the technology can uniquely address, expand adoption, reduce costs, and establish infrastructure that supports repeated use.
PacBio's approximately 25-year history demonstrates just how long, complex, and iterative this process can be.
References
This article prioritizes filings with the U.S. Securities and Exchange Commission (SEC), official government documents, and peer-reviewed scientific literature. Official announcements from PacBio and its partners are also used to establish product launch dates, transaction values, executive appointments, and other corporate events.
Corporate statements about future market opportunities, technological advantages, and anticipated outcomes are distinguished from independently established facts.
[1] Pacific Biosciences of California, Inc., “Prospectus,” Form 424B1, U.S. Securities and Exchange Commission, 2010. https://www.sec.gov/Archives/edgar/data/1299130/000119312510237221/d424b1.htm
[2] Pacific Biosciences of California, Inc., “Annual Reports,” 2010–2025. https://investor.pacificbiosciences.com/financial-information/annual-reports
[3] Pacific Biosciences of California, Inc., “Investor Relations,” Product Announcements, Corporate News, and Technology Updates, various years. https://investor.pacificbiosciences.com/
[4] Wenger, A. M., et al., “Accurate circular consensus long-read sequencing improves variant detection and assembly of a human genome,” Nature Biotechnology, 37, 1155–1162, 2019. https://doi.org/10.1038/s41587-019-0217-9
[5] Federal Trade Commission, “Illumina, Inc. and Pacific Biosciences of California, Inc., In the Matter of,” FTC Case No. 191 0035, 2019–2020. https://www.ftc.gov/legal-library/browse/cases-proceedings/1910035-illumina-incpacific-biosciences-california-inc-matter
[6] Pacific Biosciences of California, Inc., “Annual Report 2021,” Form 10-K, 2022. https://investor.pacificbiosciences.com/financial-information/annual-reports
[7] Pacific Biosciences of California, Inc., “Annual Report 2025,” Form 10-K, U.S. Securities and Exchange Commission, 2026. https://www.sec.gov/Archives/edgar/data/1299130/000129913026000034/pacb-20251231.htm
[8] Pacific Biosciences of California, Inc., “Investor Relations,” Official Announcements Concerning Second-Quarter 2026 Financial Results, Leadership Changes, Business Restructuring, and Strategic Collaborations, 2026. https://investor.pacificbiosciences.com/
Research Limitations
This article is based on publicly available information reviewed as of November 3, 2026.
Although the major technological and business turning points have been covered, several topics warrant additional investigation.
These include:
- Individual venture capital financing rounds and ownership percentages during the company's early years
- Detailed changes in management during the 2000s
- Cumulative instrument installations or sales for each sequencing platform generation
- The detailed investment returns associated with the Omniome acquisition
- Price and performance comparisons with Oxford Nanopore and Illumina
- Debt maturity and refinancing plans beyond 2026